MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that it has completed enrollment of Breeze 1, the first of two pivotal Phase 3 clinical trials in Depomed's registration program of DM-5689 for the non-hormonal treatment of menopausal hot flashes.
